Taken together, our findings suggest that MYT1L may function as a tumor suppressor that plays a pivotal role in the progression of glioblastoma cells with loss of DNA-PK function through the activation of ERK1/2 and AKT pathways and through the regulation of the expression of molecules associated with apoptosis and cell cycle regulation. This evidence concerns the gene MAPK3 and neoplasm.